Phase 1 Study of an Oxaliplatin and Etoposide Regimen in Pediatric Patients With Recurrent Solid Tumors.

Authors :: McGregor, Lisa M.
Spunt, Sheri L.
Santana, Victor M.
Stewart, Clinton F.
Ward, Deborah A.
Watkins, Amy
Laningham, Fred H.
Ivy, Percy
Furman, Wayne L.
Fouladi, Maryam
Source :: Cancer (0008543X); 2/1/2009, Vol. 115 Issue 3, p655-664, 10p
Publication Year :: 2009
Abstract: The article focuses on a study conducted to estimate the maximum tolerated dose (MTD) of an oxaliplatin and etoposide regimen in children with recurrent solid tumors. During the study, 16 patients received a total of 63 courses. In the study, Neutropenia was found to be of the dose-limiting toxicity. The study also showed that calcium and magnesium infusions did not allow escalation of the oxaliplatin dose.

Subjects :: DRUG tolerance
JUVENILE diseases
ETOPOSIDE
OXALIPLATIN
NEUTROPENIA
TUMORS

Full Text Access

Tools